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Abstract
Chronic kidney disease (CKD) affects over 10% of the global population and poses signifi-
cant challenges for societies and health care systems worldwide. To illustrate these chal-
lenges and inform cost-effectiveness analyses, we undertook a comprehensive systematic
scoping review that explored costs, health-related quality of life (HRQoL) and life expec-
tancy (LE) amongst individuals with CKD. Costs were examined from a health system and
societal perspective, and HRQoL was assessed from a societal and patient perspective.
Papers published in English from 2015 onward found through a systematic search strategy
formed the basis of the review. All costs were adjusted for inflation and expressed in US$
after correcting for purchasing power parity. From the health system perspective, progres-
sion from CKD stages 1–2 to CKD stages 3a-3b was associated with a 1.1–1.7 fold increase
in per patient mean annual health care cost. The progression from CKD stage 3 to CKD
stages 4–5 was associated with a 1.3–4.2 fold increase in costs, with the highest costs asso-
ciated with end-stage renal disease at $20,110 to $100,593 per patient. Mean EuroQol-5D
index scores ranged from 0.80 to 0.86 for CKD stages 1–3, and decreased to 0.73–0.79 for
CKD stages 4–5. For treatment with renal replacement therapy, transplant recipients
incurred lower costs and demonstrated higher HRQoL scores with longer LE compared to
dialysis patients. The study has provided a comprehensive updated overview of the burden
associated with different CKD stages and renal replacement therapy modalities across
developed countries. These data will be useful for the assessment of new renal services/
therapies in terms of cost-effectiveness.
1. Introduction
Chronic kidney disease (CKD) is a major global public health issue, affecting over 10% of the
population worldwide [1]. The problem was ranked 16th among the leading causes of death in
2016, and is expected to rise to 5th ranked by 2040 [2]. Chronic kidney disease is defined as an
abnormality of kidney function or structure for� 3 months [3] and is a significant burden for
individuals, health care systems and societies; it is associated with increased hospitalization,
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productivity loss, morbidity and early mortality. Diabetic kidney disease is the leading cause of
CKD [4]; other common causes include hypertension, glomerulonephritis and autosomal
dominant polycystic kidney disease [5]. Many individuals have no known cause of CKD.
Chronic kidney disease is classified based on abnormal urinalysis and/or renal tract struc-
ture and estimated glomerular filtration rate (eGFR), with the most advanced stage, CKD stage
5, comprising individuals with an eGFR<15 ml/min/1.73m2 including patients with end-
stage renal disease (ESRD) [1]. Chronic kidney disease is managed through treatment of its
risk factors, such as hypertension and diabetes mellitus [3]. A small proportion of patients
with CKD progress to ESRD requiring renal replacement therapy (RRT) with dialysis and/or
kidney transplantation (KTx) [6]. Dialysis treatment can be provided at home (peritoneal dial-
ysis (PD) or home haemodialysis (HHD)), or as in-centre haemodialysis (ICHD) at a satellite
dialysis unit or hospital. [7]. Conservative care is an alternate to RRT for patients who would
not have a survival or quality of life benefit from RRT or who choose not to receive RRT, and
only provides a means for management of symptoms associated with CKD [8]. In 2010,
approximately 2.62 million patients received RRT worldwide, and the numbers are expected to
double by 2030, in part due to trends in obesity and diabetes mellitus and in part due to an age-
ing population in many countries [9]. The increasing incidence of ESRD treatment can also be
linked to the improved access to ESRD services in developed countries [10].
In 2016, after Taiwan, the US showed the second highest incidence rate of RRT worldwide,
with 378 patients per million of the general American population receiving treatment for
ESRD [11].
The current scoping review aimed to provide an updated comprehensive summary of the
reported/estimated burden associated with CKD and different RRT modalities in order to
inform cost-effectiveness analyses of novel renal services/therapies. Specific objectives of this
study were (1) to investigate the costs of CKD and/or RRT from a health system and societal
perspective, (2) to explore HRQoL among CKD patients receiving or not receiving RRT, from
a societal and patient perspective, and (3) investigate LE and survival in patients with CKD
receiving or not receiving RRT.
2. Methodology
A systematic scoping review was undertaken to assess the nature, scope, and range of the exist-
ing literature on the study topic, and to produce a comprehensive synthesis of the available evi-
dence. S1 Appendix shows the PRISMA checklist for this study. A systematic scoping review
was chosen because of the potential breadth of the literature to be examined and the desire to
identify gaps in knowledge. Systematic scoping reviews merge the advantages of the scoping
review methodology (e.g. implementation of consultation exercise with key stakeholders to
validate findings) and the strengths of the systematic review method (e.g. adoption of system-
atic search strategy). This study adopted the six-stage methodological framework set by Arksey
and O’Malley [12] as follows:
2.1. Setting the research question
In order to comprehensively review the literature, a broad research question was formulated:
what are the associated societal costs of CKD and what are the HRQoL and the LE of patients
with CKD?
2.2. Identification of pertinent studies
A flexible search strategy was adopted to find relevant published citations and grey literature
(e.g. government documents and reports) on the study topic. Four key concepts were
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identified in the review question, namely, CKD, societal costs, HRQoL and LE–each being seen
as a facet of disease burden. In total, 24 search terms were operated using three separate com-
binations utilizing Boolean operators ‘AND’ and ‘OR’ (S2 Appendix).
The search technique included both automated and manual search methods in order to
avoid missing any pertinent articles. The automated search was undertaken by one author
(SE) in five databases, namely, Medline, Embase, the National Health Service Economic Evalu-
ation Database, the Health Technology Assessment Database, and the Database of Abstracts of
Reviews of Effects. Given the periodic revision and update of international CKD care guide-
lines, the search process was limited to articles published between 2015 and April 2019 to pro-
vide a comprehensive updated overview of the burden associated with the disease, while aiding
comparability. [13] We limited the search to this five-year period in order to extract cost esti-
mates from a limited, and therefore in economic terms, comparable time period.
The search strategy also included searching bibliographies of potential articles, hand search-
ing journals, as well as researching key authors, conference abstract repositories, and institu-
tional websites.
2.3. Study selection
The study only included English language articles published during the search window (2015–
2019). In an attempt to strike a balance between minimising heterogeneity while being com-
prehensive, only studies conducted in North America (Canada and US), Europe, and Australia
were included. Studies were included if they estimated health care costs and/or total societal
costs (lost productivity and out of pocket costs, including informal care, paid domestic help
and transportation), HRQoL and/or the LE of adult patients with CKD. Articles assessing
utility values, without assessing HRQoL scores were included. The following study types were
excluded: (1) studies investigating patients’ perceptions about RRT; (2) studies exploring
HRQoL among carers/family members of CKD patients; and (3) studies concerned with incre-
mental costs without estimating actual costs (e.g. the cost of a service rather than just the cost
of an addition to that service).
A two-step process was followed to select eligible studies from among the search results.
First, titles and abstracts of the retrieved articles were preliminarily screened against the inclu-
sion and exclusion criteria. Second, the potentially relevant articles were re-examined and
reviewed in full, together with the papers located from reference lists and web searches (Fig 1).
2.4. Charting the data
Standardized Microsoft Excel extraction forms were used to extract pertinent data from the
included articles. These incorporated authors’ names, article title, country of authorship, study
objectives, study methodology, study participants, and main findings. With respect to the
reporting of costs, to aid comparability, the study adjusted for inflation and purchasing power
parity using a two-step process. Costs in the included studies were first adjusted for inflation
in their country of origin using the relevant consumer price index for health to express these
in a common year’s values and then adjusted for purchasing power parity using Organisation
for Economic Co-operation and Development (OECD) published data [14,15]. All costs were
expressed in US$ 2019.
2.5. Collating, summarizing and reporting the results
The data analysis phase comprised two major steps in order to reliably categorize complex
data, and to answer the research question in such a way that the outputs were consistent with
the study aim and objectives. First, the extracted data were subjected to numerical synthesis in
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order to map the available evidence as outlined in the review question. Second, the data were
distributed among three major subsections addressing the study objectives separately, while
considering the implications of the study findings to improve the validity of the study and to
inform future research.
2.6. Consultation exercise
The study included a consultation with four nephrologists from the UK and Ireland. This
involved the circulation of a preliminary copy of the review (i.e. aims, objectives, search strat-
egy and major findings) together with a brief survey to explore their opinions on its findings
(S3 Appendix). The aim of the survey was to validate the study findings. The consultation out-
put was taken into consideration in the subsequent discussion of the study.
3. Results
In total, 1991 potential papers were retrieved from the searched databases, with an additional
24 located from web searches and bibliographies. Of these, only 78 were ultimately included in
the review (Fig 1). The majority of the included studies were conducted in Europe (62%), fol-
lowed by North America (31%), and Australia (7%). Two study designs predominated: cross-
sectional study (38%) and cohort study (33%) (S1 Table).
3.1. Costs of CKD
A total of 37 studies estimating health care and societal costs of CKD and RRT were included.
These investigated costs associated with different stages of CKD, and costs of different treat-
ment modalities as follows:
3.1.1. Costs of different CKD stages. The annual societal and health care costs increased
with the progression of each CKD stage, regardless of the cause of CKD or the country of ori-
gin (Tables 1 and 2).
Fig 1. Flow diagram of the studies included in the final analysis.
https://doi.org/10.1371/journal.pone.0230512.g001
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Table 1. Per patient mean annual total health care costs (in 2019 US $) for different CKD stages or ESRD (Mean ± SD / (95% CI))&.
Country Study type Participants Any CKD CKD 1 CKD 2 CKD 3a CKD 3b CKD 4 CKD 5 ESRD Reference
US Retrospective cohort
study
250,742 DKD patients 40,259δ N/A N/A N/A N/A N/A N/A N/A [16]
US Retrospective cohort
study
1,274 ADPKD patients with
ESRD
N/A N/A N/A N/A N/A N/A N/A 64,040# [17]
Sweden Prospective cohort study. 2432 Patients with CKD N/A N/A N/A N/A N/A 12,200� N/A [18]
Denmark Cross-sectional 243 ADPKD patients N/A 3,675 (1,931–6,666) #� 6,190 (4,703–8,392) #� N/A [19]
Norway Cross-sectional 243 ADPKD patients N/A 3,865 (1,870–6,930) #� 8,009 (5,112–11,846) #� N/A [19]
Sweden Cross-sectional 243 ADPKD patients N/A 3,181 (1,780–5,595) #� 5,367 (4,053–7,192) #� N/A [19]
Finland Cross-sectional 243 ADPKD patients N/A 4,417 (2,671–7,438) #� 7,070 (5,513–9,254) #� N/A [19]
US Case-control study 106,050 patients aged�65
with CKD
N/A N/A 16,692 24,147 31,596 53,186 100,594 [20]
Italy Prospective cohort study 864 patients with CKD 3,599 (3,255–
3,942)
1,545 (1,147–
1,944)
1,990 (1,604–
2,376)
2,161 (1,797–
2,524)
3,377 (2,783–
3,970)
5,481 (4,472–
6,489)
7,207 (5,639–
8,773)
N/A [21]
UK Secondary analysis of the
SHARP data
7,246 CKD patients N/A 1,600+ 5,604+ 19,648+ N/A [22]
England Analysis of NHSRC data 211,215 CKD patients 16,377+ N/A N/A N/A N/A N/A N/A N/A [23]
US Retrospective cohort
study
4234 ADPKD patients with
CKD
N/A 26,367#/ 21,761#/ 26,982#/ 39,183 #/ N/A N/A [24]
US Cross- sectional 18,380 ESRD patients aged
�18 years
N/A N/A N/A N/A N/A N/A N/A 54,782±
132,992
[25]
Canada Cohort study 219,641 patients with CKD 11,064 N/A N/A 9,668 15,215 17,618 33,202 N/A [26]
US Cross-sectional 2,053 patients with DKD 25,150 (19,806–
30,495)δ
N/A N/A N/A N/A N/A N/A N/A [27]
US Analysis of MEPS-HC 187,341 patients aged�18 44,699 (38,896–
50,501)
N/A N/A N/A N/A N/A N/A N/A [28,29]
Italy Retrospective cohort
study
130,502 DKD patients N/A N/A N/A N/A N/A N/A N/A 20,110±
21,433δ
[30]
Italy Retrospective cohort
study
1067 CKD & ESRD patients N/A N/A 3,080± 4,518 N/A N/A [31]
Italy Cross-sectional 484 patients with CKD N/A N/A N/A N/A N/A 5,217± 5,491 6,859± 5,457 N/A [32]
N/A N/A N/A N/A N/A 7,587δ N/A
US Medicare data analysis Patients aged�65 with CKDO 23,036 20,104 22,318 30,080 N/A [33]
26,194δ 22,640δ 25,683δ 34,073δ N/A
US Medicare data analysis Patients aged�65 with CKDO 22,493 19,847 22,054 29,448 N/A [34]
25,015δ 22,701δ 25,280δ 32,853δ N/A
The
Netherlands
Case-control study 18,340 patients
with CKD 4/5
20–44
years
N/A N/A N/A N/A N/A 10,098 N/A [35]
45–64
years
N/A N/A N/A N/A N/A 13,539 N/A
65–74
years
N/A N/A N/A N/A N/A 15,172 N/A
�75
years
N/A N/A N/A N/A N/A 13,958 N/A
Australia Cohort study 6138 patients with CKD N/A 2,273 (1,945–2,600) � 2,916 (2,305–3,528) � 12,157 (4,747–37,480) � N/A [36]
& Most studies estimated total health care costs, irrespective whether it is or is not related to CKD, based on primary care, in-patient, out-patient, diagnostics and
medications/pharmaceuticals with exception of the following;
+ Studies estimated health care costs based on in-patient costs.
� Studies estimated health care costs solely related to CKD.
Cells are merged for studies which estimated combined cost for stages 1 &2, 1–3, 3a &3b, and 4 &5. Abbreviations: SD: standard deviation; CI: confidence interval;
CKD: chronic kidney disease; DKD: diabetic kidney disease; ADPKD: autosomal dominant polycystic kidney disease; ESRD: end-stage renal disease; SHARP: The Study
of Heart and Renal Protection; NHSRC: National Health Service Reference Cost; MEPS-HC: The Medical Expenditure Panel Survey Household Component; N/A: non-
available.
# Costs in patients with ADPKD.
δCosts in patients with DKD.
/Costs were extrapolated from biannual or monthly costs.
O Number of patients is non-available.
https://doi.org/10.1371/journal.pone.0230512.t001
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From a health system perspective, the per patient mean annual total health care costs ran-
ged from $1,600 to $25,037 for patients with CKD stages 1–3, whereas patients with CKD
stages 4–5 incurred higher costs ranging from $5,367 to $53,186. ESRD costs were even higher,
ranging from $20,110 to $100,593. From a societal perspective, non-dialysis costs of CKD
stages 1–3 were in the range $4,803-$15,001, whereas CKD stages 4–5 showed the highest
costs ranging from $10,750 to $28,428 in Europe (Table 2). Turchetti et al., and Erikson et al.,
showed that productivity loss for patients with CKD stages 4–5 accounted for <1/10 and 2/3
of the total societal costs in Italy and the Nordic countries, respectively [19,32].
3.1.2. Costs of different treatment modalities for ESRD. Eighteen studies investigated
annual costs of different dialysis modalities, from a health system perspective (Table 3).
In general, patients receiving haemodialysis (HD) incurred higher costs compared to
patients managed by PD. Concerning place of dialysis delivery, HHD costs were 49–65% of
ICHD costs [38,40,44]. Furthermore, 11 studies estimated the annual health care costs of KTx
in the range of $14,067 to $80,876 (Table 3). Studies showed that costs in the first year after
KTx were substantially higher than in subsequent years, where they decreased dramatically.
The costs of KTx were 21–88% of dialysis costs (Table 3). From a societal perspective, Eriksson
et al. showed that costs incurred by patients who underwent KTx were 34–43% of costs
incurred by dialysis patients (Table 2). Finally, Phair et al. conducted a cohort study specifically
related to conservative (non-RRT) care for ESRD patients in England and Northern Ireland.
They estimated the per patient mean annual health care costs to be US $7,411 (95% CI: 351–
14,471) for patients receiving this care modality [8].
Table 2. Mean annual societal costs & productivity loss (in 2019 US $) incurred by patients with CKD and on RRT (Mean ± SD / (95% CI)).
Country Cost & productivity loss CKD 1–3 CKD 4 CKD 5 Dialysis KTx@ Reference
Denmark Societal cost 10,431 (7,190–14,321) # 18,600 (13,848–23,795) #δ 100,758 (92,754–108,954) # 36,430 (29,801–43,672) # [19]
Productivity loss 6,717 (4,175–9,879) F 12,076 (8,272–16,202) #δF 11,982 (7,792–16,020) F 10,576 (7,142–14,360) F
Finland Societal cost 10,261 (7,261–13,977) # 18,971 (14,428–24,044) #δ 87,106 (80,577–94,964) # 33,515 (27,241–40,524) # [19]
Productivity loss 5,810 (3,556–8,537) F 11,617 (7,914–15,644) #δF 8,151 (5,511–10,593) F 8,998 (6,078–12,476) F
Norway Societal cost 15,001(10,469–20,282) # 28,428 (20,654–37,285) #δ 106,614 (94,981–120,328) # 36,702 (27,876–46,595) # [19]
Productivity loss 11,082 (7,004–15,737) F 19,951 (13,970–26,285) #δF 19,783 (12,969–25,893) F 18,013 (12,334–24,087) F
Sweden Societal cost 10,274 (7,148–13,893) # 19,556 (14,476–25,072) #δ 92,440 (85,156–99,702) # 31,557 (25,169–38,880) # [19]
Productivity loss 7,060 (4,354–10,155) F 13,910 (9,729–18,319) #δF 12,745 (8,501–16,609) F 12,325 (8,367–16,494) F
Italy Societal cost N/A 9,734± 8,204 11,766± 8,529δ N/A N/A [32]
Productivity loss N/A 489± 2811� 1,045± 4,324δ� N/A N/A
Australia Societal cost 4,803 17,488δ N/A N/A [37]
Productivity loss N/A N/A N/A N/A
Nordics Societal cost 11,920# 20,142#δ 88,943# 37,849# [38]
Productivity loss N/A N/A N/A N/A
Productivity losses in all studies were estimated using the human capital approach. All studies estimated productivity loss for all patients aged�18 years, including those
over 65 years. In all studies, lost productivity was estimated among all patients in and not in the workforce. Societal costs in all studies were based on total health care
costs, productivity loss, out of pocket costs, such as informal care and paid domestic help. Cells are merged for studies which estimated combined cost for stages 4 & 5.
Abbreviations: SD: standard deviation; CI: confidence interval; CKD: chronic kidney disease; RRT: renal replacement therapy; KTx: kidney transplantation; N/A: non-
available.
@ Combined KTx costs for those in the first or subsequent years.
# Costs in patients with ADPKD.
δ Cost in patients without dialysis.
� Productivity costs were estimated among patients and care givers.
F Productivity loss was estimated in CKD patients only, with no estimation for care givers.
https://doi.org/10.1371/journal.pone.0230512.t002
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Table 3. Mean annual health care costs (in 2019 US $) of different dialysis modalities and kidney transplantation (Mean ± SD/ (95% CI)).
Country Study type Participants KTx@ 1st year
after KTx
Subsequent
years after
KTx
Any
dialysis
Conventional HD PD References
HHD ICHD Any PD APD CAPD
Sweden Cohort
study
2432 Patients on
RRT
19,698 N/A N/A N/A N/A 111,326 74,471 N/A N/A [18]
Denmark Cross-
sectional
243 ADPKD
patients
25,718
(20,858–
31,208) #
N/A N/A 87,517
(81,751–
94,503) #
N/A N/A N/A N/A N/A [19]
Finland Cross-
sectional
243 ADPKD
patients
24,400
(19,501–
30,242) #
N/A N/A 77,883
(72,654–
84,620) #
N/A N/A N/A N/A N/A [19]
Norway Cross-
sectional
243 ADPKD
patients
18,498
(13,183–
25,139) #
N/A N/A 85,070
(76,481–
95,863) #
N/A N/A N/A N/A N/A [19]
Sweden Cross-
sectional
243 ADPKD
patients
19,118
(14,994–
24,082) #
N/A N/A 78,646
(73,743–
84,612) #
N/A N/A N/A N/A N/A [19]
UK Analysis of
SHARP
data
7,246 CKD and
ESRD patients
N/A 37,321
(36,449–
38,195) +
1,742
(1,484–
1,999) +
35,385
(35,241–
35,529) +
N/A N/A N/A N/A N/A [22]
US Cohort
study
4,234 ADPKD
patients on RRT
80,876#/ N/A N/A 145,215#/ N/A N/A N/A N/A N/A [24]
The
Netherlands
Case-
control
study
13,734
patients
on RRT
20–
44
yrs
18,157 N/A N/A 105,293 N/A 105,579 94,986 N/A N/A [35]
45–
64
yrs
18,219 N/A N/A 110,123 N/A 111,275 97,796 N/A N/A
65–
74
yrs
20,472 N/A N/A 107,443 N/A 108,205 96,654 N/A N/A
�75
yrs
19,387 N/A N/A 100,215 N/A 100,668 92,767 N/A N/A
Nordics Cross-
sectional
243 ADPKD
patients
21,358 # N/A N/A 72,719 # N/A N/A N/A N/A N/A [37]
Canada Cost
minimiza-
tion study
Patients on RRT
O
N/A N/A N/A N/A 31,734 49,071 29,542 N/A N/A [38]
France Simulati-on
model
covering 15
years
Incident
ESRD
patients O
18–
44
yrs
N/A N/A N/A N/A N/A N/A N/A 35,020 35,100 [39]
N/A N/A N/A N/A N/A N/A N/A 59,529δ 58,954δ
45–
69
yrs
N/A N/A N/A N/A N/A N/A N/A 47,976 47,883
N/A N/A N/A N/A N/A N/A N/A 80,081δ 80,041δ
France Analysis of
FNHIF data
47,862 ESRD
patients�18
years
14,067/ N/A N/A N/A 52,416/ 92,690/ N/A 56,240/ 46,947/ [40]
23,199δ/ N/A N/A N/A 66,188δ/ 107,078δ/ N/A 68,983δ/ 56,922δ/
Italy Clinical trial 340 patients
with ESRD
N/A N/A N/A N/A N/A 71,191 N/A N/A N/A [41]
Sweden Before- after
study¥
1220 ESRD
patients
N/A 73,661
±86,236
13,667 N/A N/A N/A N/A N/A N/A [42]
England Analysis of
UKRR data
20,235 patients
on RRT
N/A 12,266F% 3,980F% N/A N/A 9,646F% 9,009F% N/A N/A [43]
N/A 15,381δ
F%
N/A N/A N/A 14,436δF% N/A N/A N/A
UK Cross-
sectional
Patients on RRT
O
21,534 N/A N/A N/A 14,616 29,665 16,067 N/A N/A [44]
(Continued)
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3.2. HRQoL associated with CKD
Thirty-six studies investigating the HRQoL associated with CKD and different treatment
modalities were included. These studies used different HRQoL assessment tools, which com-
prised the EuroQol-5D (EQ-5D) [eight studies], the EuroQol visual analogue scale (EQ-VAS)
[three studies], the Kidney Disease Quality of Life Short Form (KDQOL-SF™) [30 studies], and
the Health Utilities Index (HUI) [one study].
3.2.1. The EQ-5D and EQ-VAS instruments. The EQ-5D tool is a validated generic mea-
sure used to assess five dimensions of health (mobility, self-care, usual activities, pain and anxi-
ety/depression), which can be converted into a single index score reflective of societal
preferences [51]. The EQ-VAS is used for rating patients’ health using a scale ranging from 0
(worst health), to 100 (best health) [51]. The EQ-5D index scores were in the range of 0.80–
0.86 for CKD stages 1–3 and decreased to 0.73–0.79 for CKD stages 4–5 (Table 4).
Similarly, CKD stages 4–5 were associated with lower VAS scores compared to CKD stages
1–3 (Table 4). For RRT modalities, patients receiving dialysis had lower EQ-5D scores (0.58–
0.68) than patients with a kidney transplant (0.82–0.83) (Table 4).
Table 3. (Continued)
Country Study type Participants KTx@ 1st year
after KTx
Subsequent
years after
KTx
Any
dialysis
Conventional HD PD References
HHD ICHD Any PD APD CAPD
US Cohort
study
181 ESRD
immigrants
N/A N/A N/A 108,776/ N/A N/A N/A N/A N/A [45]
Italy Administr-
ative
databases
analysis
276 patients on
RRT
N/A 58,218 N/A 48,835 N/A N/A N/A N/A N/A [46]
Italy Cohort
study
1067 CKD
patients
N/A N/A N/A N/A N/A 55,341±
17,646
40,460±
12,469
41,204±
11,013
39,709±
14,020
[31,47]
US Medicare
data
analysis
Patients on
different RRT O
34,343 N/A N/A N/A N/A 92,364 77,582 N/A N/A [48]
US Medicare
data
analysis
Patients on
different RRT O
34,974 N/A N/A N/A N/A 91,477 76,601 N/A N/A [49]
Sweden Cohort
study
3120 KTx
recipients
N/A 76,293 15,564 N/A N/A N/A N/A N/A N/A [50]
& Most studies estimated total health care costs based on primary care, in-patient, out-patient, diagnostics and medications/pharmaceuticals with exception of the
following;
+ Studies estimated health care costs based on in-patient costs.
% Studies estimated health care costs based on in-patient and out-patient costs
Abbreviations: SD: standard deviation; CI: confidence interval; CKD: chronic kidney disease; ADPKD: autosomal dominant polycystic kidney disease; ESRD: end-stage
renal disease; RRT: renal replacement therapy; KTx: kidney transplantation; HD: haemodialysis; HHD: home haemodialysis; ICHD: in-center haemodialysis; PD:
peritoneal dialysis; APD: automated peritoneal dialysis; CAPD: continuous ambulatory peritoneal dialysis; SHARP: The Study of Heart and Renal Protection; FNHIF:
The French National Health Insurance funds; UKRR: UK Renal Registry data; N/A: non-available.
@ Combined KTx costs for those in the first or subsequent years.
# Costs in patients with ADPKD.
F Excluding the costs of maintenance dialysis and transplant surgery.
δ Costs in patients with diabetic kidney disease.
/ Costs were extrapolated from biannual or monthly costs.
O Number of patients is non-available.
¥ Type of study that measures outcomes before and after the implementation of an intervention.
https://doi.org/10.1371/journal.pone.0230512.t003
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3.2.2. The KDQOL-SF™ tool. The KDQOL-SF is a self-report measure consisting of
generic and kidney-specific parts [60]. The generic part comprises eight domains that can be
summarized in two summary scores; a physical component score (PCS) and a mental compo-
nent score (MCS), whereas the specific part contains 12 domains addressing particular issues
for CKD patients.
Patients with CKD stages 4–5 had the lowest mean PCS and MCS at 34.8–49.2 and 50.3–
60.1 respectively [53,61–67] (S2 Table). For RRT treatments, KTx recipients reported higher
mean generic and specific scores relative to those on dialysis [68–83] (S2–S4 Tables). Nagaraja
et al. [44] converted the SF-36 data into SF-6D utility scores and showed a similar relationship;
kidney transplantation was associated with better mean SF-6D utility scores relative to HD
(0.65± SD: 0.13 vs 0.52± SD: 0.11, respectively).
Peritoneal dialysis was associated with better scores than HD for both generic and kidney
specific domains [84,85]. Nagaraja et al. [44], on the other hand, reported that mean SF-6D
utility scores among patients managed by PD were similar to those receiving HD (0.53 ± 0.10
vs 0.52 ± 0.11, respectively). Regarding place of dialysis delivery, Nagaraja et al. [44] reported
no significant difference between mean SF-6D utility scores of HHD and ICHD (0.52 ± 0.15 vs
0.52 ± 0.11, respectively).
Table 4. Mean EQ-5D and VAS scores across different CKD stages and treatment modalities (Mean ± SD / (95% CI)).
Country Participants Tool CKD 1/2 CKD 3 CKD 4 CKD 5 HD PD KTx Reference
UK 512 KTx
recipients
EQ-5D-
5L
N/A N/A N/A N/A N/A N/A 0.83 [52]
VAS N/A N/A N/A N/A N/A N/A N/A
Nordics 243 patients EQ-5D-
3L
0.86 ± 0.16# 0.79 ± 0.23# 0.68 ± 0.30# 0.82±
0.21#
[53]
VAS 81.7 ± 16.6# 70.4 ± 22.7# 60.1 ± 20.8# 76.7±
16.9#
Europe 1336 CKD
patients
EQ-5D-
3L
N/A 0.76 N/A N/A N/A N/A [54]
VAS N/A N/A N/A N/A N/A N/A
Turkey 60 patients on
RRT
EQ-5D-
3L
N/A N/A N/A N/A 0.60±
0.29
0.68±
0.33
N/A [55]
VAS N/A N/A N/A N/A 66.7±
22.3
58.1±
13.1
N/A
France, Germany, Italy, UK,
Spain, US
2233 CKD
patients
EQ-5D-
3L
N/A 0.82 0.78 0.71 N/A N/A N/A [56]
VAS N/A N/A N/A N/A N/A N/A N/A
UK 745 CKD patients EQ-5D-
3L
0.85 (0.70–
1)
0.80 (0.68–
1)
0.74 (0.62–
0.85)
0.73 (0.62–
1)
N/A N/A N/A [57]
VAS 50 (75–82) 70 (50–80) 60 (50–80) 55 (50–80) N/A N/A N/A
England & Ireland 893 patients on
HD
EQ-5D-
3L
N/A N/A N/A N/A 0.58±
0.33
N/A N/A [58]
VAS N/A N/A N/A N/A 58.3±
23.9
N/A N/A
Australia 95 CKD patients EQ-5D-
3L
N/A N/A N/A 0.75± 0.20 N/A N/A N/A [59]
VAS N/A N/A N/A N/A N/A N/A N/A
Cells are merged for studies which estimated combined score for stages 1–3, 3–4, and 4–5, as well as HD & PD. Abbreviations: SD: standard deviation; CI: confidence
interval; CKD: chronic kidney disease; HD: haemodialysis; PD: peritoneal dialysis; KTx: kidney transplantation; EQ-5D: Euroqol-5D; VAS: visual analogue scale; N/A:
non-available
# Scores in patients with ADPKD.
https://doi.org/10.1371/journal.pone.0230512.t004
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Finally, Shah et al. [86,87] indicated that ESRD elderly patients managed with conservative
care exhibited significantly higher mean SF-6D utility scores compared to those receiving dial-
ysis (0.65 ± 0.15, vs 0.61 ± 0.13, respectively).
3.2.3. The HUI system. The HUI system is a generic, preference-based measure used to
produce utility scores providing a summary index of HRQoL on a (0.0–1.0) scale [88]. A
cross-sectional study by Garg et al. [76] reported that HHD was associated with better mean
scores among ESRD patients, relative to ICHD (0.64 ± 0.34 vs 0.53 ± 0.38, respectively).
3.3. LE among CKD patients
In total, seven studies addressing LE and survival among CKD patients were included.
Bowling et al. [89] conducted a cohort study in 357,632 CKD patients aged� 70 years and
showed that median survival time decreased with progression in either age or CKD stage;
patients aged� 85 years had the lowest survival ranging from 1.9 (CKD stage 4) to 3.2 years
(CKD stage 2). Tamura et al. [90] estimated survival among 73,349 older ESRD patients (� 60
years) initiating dialysis at different kidney function levels. The study revealed that median sur-
vival was diminished upon initiating dialysis at higher GFRs as well as with older age. For exam-
ple, patients aged� 85 years exhibited the lowest survival from initiating dialysis varying from
1.8 years at an eGFR of 9–12 ml/min/1.73 m2) to 2.0 years at an eGFR< 6 ml/min/1.73 m2.
Steenkamp et al. [91] analyzed the 2014–2015 UK renal registry data of 7,626 ESRD
patients, and showed that survival probabilities (adjusted to age 60) for 15 months after start-
ing RRT (dialysis or KTx) was 90.1%. On the other hand, Couchoud et al. [92] investigated
restricted mean survival time amongst 67,258 ESRD patients according to their age, gender,
and diabetes status for the first 15 years following RRT initiation. The study demonstrated that
both males and females aged 18 with diabetes experienced lower survival time (12.7 years for
either gender) compared to those without diabetes (males; 14.3 years and females; 14.2 years).
In contrast, survival time in both diabetic and non-diabetic patients aged 90 years was nearly
similar (males: 1.6 vs. 1.8 years, respectively and females: 1.9 vs. 2 years, respectively).
Two reports by the US Renal Data System (USRDS) [93,94] compared survival probabilities
for ESRD patients on HD and PD over the period (2000–2009), and showed that HD was consis-
tently associated with lower survival than PD. The same reports by the USRDS also investigated
the difference in survival between different KTx types over the same period, and demonstrated
that living donor transplant recipients always showed higher survival, relative to deceased donor
kidney transplant recipients. The 2016 USRDS report [94] showed that KTx was associated with
higher LE (7.7 for males and 8.7 for females) than dialysis (3.2 for males and 3.5 for females) in
the age group 75–79 years, with similar results shown across all age groups.
Finally, a cohort study by Verberne et al. [95] compared survival time among 311 ESRD
patients (age� 70 years) receiving either RRT (dialysis or KTx) or conservative care and
reported survival of 3.1 year and 1.5 years, respectively.
3.4. Consultation exercise
All nephrologists concurred with the review findings in relation to the increase in costs and
decrease in HRQoL as CKD stage advanced. The nephrologists suggested that costs at different
stages could vary considerably depending on what is bundled into the episode of care (e.g. hos-
pital clinic or admission costs, and training of staff), aetiology of CKD and associated comor-
bidities. These factors may help explain the heterogeneity with respect to costs found in this
study. The nephrologists agreed that societal costs might be inaccurately estimated and poorly
captured in the current reports. Examples of societal costs include productivity losses (valued,
for example, through the human capital approach) amongst CKD patients, donors and/or
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carers due to either absenteeism (work absences) or presenteeism (reduced productivity
among those with CKD in work). Societal costs also include transportation costs, and avoid-
able co-morbidity such as depression occasioned while on HD and awaiting transplantation.
The nephrologists attributed the higher costs in the US, relative to Europe, to systems that
carefully itemize more costs. In the US, in contrast to Europe, there may be more comprehen-
sive attribution of health care expenditure resulting in higher unit costs (i.e. prices for drugs
and procedures), higher rates of comorbidities in CKD/ESRD patients (those presenting may
have been sicker), and a lower threshold for investigation in some clinical settings (whether as
a result of a higher likelihood to practice defensive medicine, an ease of access to diagnostic
investigations or an ability to recoup costs from insurers). They suggested that HRQoL data
should be interpreted cautiously due to potential confounders (e.g. comorbidities and higher
prevalence of depression amongst CKD patients).
Concerning different RRT modalities, all nephrologists confirmed that KTx is accepted to
be consistently associated with lower costs, better HRQoL and longer survival compared to
dialysis. They also supported the review findings regarding the substantial decline in costs in
subsequent years following the first year after KTx, and attributed that to reduced burden of
procedures, hospitalizations and outpatient appointments following stabilization of post-trans-
plant follow-up and to the availability of relatively cheap generic immunosuppressive drugs.
The nephrologists suggested that HRQoL and LE data for KTx might be subject to a degree of
selection bias, as healthier patients are more likely to be transplanted.
All nephrologists acknowledged that the review findings would be useful for commissioners
considering the cost-effectiveness of new therapies. They also advised that the study would
inform future research, resource allocation, training of health personnel, preventative health
care, and opportunities for reducing costs (e.g. telehealth, standardisation of medication use,
cost negotiations with pharma).
4. Discussion
This scoping review has explored the reported burden associated with CKD in order to inform
provision of convenient renal services and economic evaluations of innovative therapies.
While broadly consistent with the assumptions and experiences of practicing nephrologists,
the findings of this review provide a deeper quantitative understanding of the influence of
CKD on costs, HRQoL and LE in developed countries during the last five years.
The results showed great variations in costs across different CKD stages, where costs sub-
stantially increased with each advance in CKD stage. Most studies (86%) estimated total health
care costs among CKD patients. From the health system perspective, the progression from
CKD stages 1–2 to CKD stages 3a-3b was associated with a 1.1–1.7-fold increase in per patient
mean annual costs, with CKD stages 1–2 demonstrating the lowest costs ($1,768-$20,104),
with Europe and the US at the lower and the higher limits of the range, respectively. The tran-
sition from CKD stage 3 to CKD stages 4–5 was associated with a 1.3–4.2-fold rise in costs,
with ESRD showing the highest costs ranging from $20,110 to $100,593, with Europe and the
US at the lower and the higher limits of the range, respectively. Although health care costs of
CKD show some variation, they are consistent in the sense that the US and Europe have the
highest and lowest costs for all stages, respectively. The substantial variation between Europe
and the US may be linked to differences in health care accountancy, difference in clinical prac-
tices (e.g. different threshold for investigation in some clinical places) and/or differences in
the cost of care between countries [96]. While costs vary between countries in a manner that
would require further research to explain, the increase in costs with advanced CKD stages is
consistent within country analyses.
PLOS ONE The impact of chronic kidney disease on westernized societies from a health economics perspective
PLOS ONE | https://doi.org/10.1371/journal.pone.0230512 March 24, 2020 11 / 19
The review produced limited data addressing costs from a societal perspective in Europe
and none in the US. These costs were also highest amongst patients with CKD stages 4–5
($10,750- $28,428). Productivity loss was highest in the Nordic countries, accounting for 2/3 of
the total societal costs among patients with CKD stages 4–5 [19]. Despite the potential time
commitment involved in dialysis and/or in transplantation, there has been limited evidence
with respect to estimation of productivity losses associated with RRT. Similarly, while previous
research has documented the relationship between dialysis and depression [97], and the poten-
tial impact of depression on productivity [98], there is also a gap in research examining the
impact of comorbidities on the productivity of ESRD patients.
Different HRQoL assessment tools showed variations in HRQoL scores across CKD stages,
where scores showed a notable decrease with each progressive CKD stage. The transition from
CKD stages 1–3 to CKD stages 4–5 was associated with a decrease of 8–11% in mean EQ-5D
index scores, with CKD stages 4–5 showing the lowest scores ranging from 0.74 to 0.79. A sys-
tematic literature review of 21 studies from developed countries showed that mean EQ-5D
scores among patients with type 2 diabetes (without complications) were in the range of 0.71–
0.94 [99]. A systematic review of 60 studies from westernized societies showed that mean EQ-
5D score was even lower for the late heart failure stages (0.51) [100]. These low scores revealed
the poor outcomes associated with these interrelated chronic diseases, highlighting the need
for effective preventive measures to slow their progression.
This study produced limited LE data among CKD patients, where available this suggested
that LE substantially decreased with each age group and with worse kidney function. Similar
findings have also been reported by Turin et al. in a large abridged life table analysis study in
Canada [101]. The low survival among older patients starting dialysis at higher eGFR levels is
likely confounded by the indications to start dialysis (i.e.co-morbidities such as heart failure or
respiratory disease).
Our study explored costs and outcomes associated with different CKD treatment modali-
ties. From a health system perspective, the costs of HD were 1.1–1.8-fold those of PD. This has
also previously been reported in a cohort study by Berger et al. [7]. Regarding place of dialysis
delivery, costs of ICHD were 1.5-2-fold those of HHD. The study results highlighted the sub-
stantial variations in transplantation costs, which were estimated to be in the range of $14,067
to $31,115, and $34,343 to $80,876, from a health system perspective, in Europe and the US,
respectively. This considerable variation may be linked to difference in health care accoun-
tancy, discrepancy in practices between countries or simply differences in the cost of care
between countries. Our study demonstrated that costs of dialysis were 1.1-6-fold and 2.3–
2.9-fold those of KTx, from a health system and societal perspective respectively. Among all
treatment modalities, KTx exhibited the highest mean EQ-5D scores, ranging from 0.82 to
0.83. Physical and mental component scores were also highest among patients with KTx, and
were reported to be in the range of 42–47 and 43–54, respectively. This has also been reported
in a systematic review of 110 studies by Tonelli et al. [6]. Our study also showed that KTx was
associated with higher LE among both women and men across all age groups compared to
dialysis modality though the potential for selection bias effects here must be borne in mind.
Not unsurprisingly, conservative care had the lowest health care costs ($7,411) as shown by
Phair et al. [8], though these results should be treated with some caution given the sample size
(the number of participants who completed this study (n = 8)).
5. Strengths and limitations
This review adopted a comprehensive systematic search strategy for scoping literature to
address its objectives. A broad range of study designs/methodologies from both recent peer-
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reviewed and non-peer reviewed literature were included. Furthermore, costs in this study
were adjusted for inflation and purchasing power parity to improve comparability. This study
also considered a consultation exercise with nephrologists. The review nevertheless still had
some limitations. The authors only assessed and included English language articles, which
posed a possibility of missing potential papers from continental Europe. The quality of the
included studies was not assessed in order to include an extensive range of evidence from both
peer-reviewed and grey literature and provide a better understanding of the burden associated
with CKD. This review included only studies from North America, Europe, and Australia,
which may not make the study findings transferable to developing countries, where the deliv-
ery of health care services is different and RRT is not available for many ESRD patients. Since,
most studies examined total healthcare costs, irrespective of whether it is related or not related
to CKD, the itemisation of all services and costs was infeasible.
6. Conclusions and implications
Costs and outcomes associated with CKD varied considerably across different stages. From a
health system perspective, the transition from CKD stage 3 to CKD stages 4–5 was associated
with a 1.3–4.2-fold increase in costs, with ESRD showing the highest costs ($20,110-$100,593).
The progression from CKD stages 1–3 to CKD stages 4–5 was associated with a decline of
8–11% in mean EQ-5D index scores, with CKD stages 4–5 demonstrating the lowest scores
(0.74–0.79). Recent studies of LE associated with different CKD stages in different countries
have been limited in number and scope. Amongst treatment modalities, KTx showed the low-
est costs ($14,067-$80,876), highest EQ-5D scores (0.82–0.83), and longest LE among both
males and females across all age groups.
In addition to identifying gaps in knowledge, the current study contributes to a better
understanding of the economic costs likely to attend increases in CKD prevalence, informing
health care planning and resourcing in developed countries. This study can also inform the
development of cost-effectiveness models of novel therapies that prevent or slow the progres-
sion of CKD. Based on the study findings, the following areas are recommended for future
research;
• Investigation of CKD aetiology-specific costs and HRQoL as they could substantially vary
depending on aetiology of CKD.
• A more comprehensive and consistent estimation of societal costs associated with different
CKD stages and RRT modalities with particular emphasis on productivity losses and costs
related to induced conditions such as depression.
• A careful itemization of healthcare costs aspects and examining whether they are paid for by
a third part or out of pocket.
• Conducting abridged life table analyses for estimation of LE across different CKD stages in
different countries.
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